US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) ...Middle East

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic...

Read More Details
Finally We wish PressBee provided you with enough information of ( US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) )

Also on site :

• Israel blocks Greta Thunberg’s ship from reaching Gaza, group says
• Israeli forces halt aid boat carrying Greta Thunberg and detain activists
• NYT Connections Sports Edition Today: Hints and Answers for June 9